Precision GLP-1 tracking

Your dose. Your schedule. Your data.

Mynim is the GLP-1 tracker built for microdosers. Live concentration curves. Smart site rotation. Real pharmacokinetic math. Not another weekly shot reminder.

Download on the App Store
$1.99/month after trial. Cancel anytime.
Mynim app showing concentration curve at steady state

You're not doing this the standard way. Why is every app built like you are?

You split your doses. You inject more often than once a week. You track half-lives in your head and wonder what your actual drug levels look like between shots.

You've done the research. You know what bioavailability means. You've read the studies.

But every GLP-1 app out there assumes you take one shot per week and want a reminder about it. That's it. That's the whole product.

You deserve better tools than a calendar notification.

Pharmacokinetics. On your phone.

Most people taking GLP-1 medications have no idea what their blood concentration looks like between doses. They feel good, they feel bad, they don't know why.

Mynim models your concentration curve in real time using the published pharmacokinetic data for your specific medication. Semaglutide. Tirzepatide. GLP-1/GIP combinations.

You see the rise. You see the peak. You see the taper. And when you're microdosing, you see how multiple small doses create a different concentration profile than a single weekly injection.

That's not a gimmick. That's information you can act on.

ng/mL hours
01

See what's happening inside you. In real time.

Mynim calculates your active drug concentration using actual pharmacokinetic modeling. Half-life, absorption rate, bioavailability. Real math, not estimates.

Watch your levels rise after a dose and taper as your body metabolizes. Know exactly where you stand before your next injection.

This isn't a graph someone designed to look clinical. It's a graph that IS clinical.

Mynim dashboard showing concentration at steady state Concentration curve with mood overlay Injection site rotation map Dose and symptom history
Mynim dashboard with concentration data
01

See what's happening inside you. In real time.

Mynim calculates your active drug concentration using actual pharmacokinetic modeling. Half-life, absorption rate, bioavailability. Real math, not estimates.

Watch your levels rise after a dose and taper as your body metabolizes. Know exactly where you stand before your next injection.

This isn't a graph someone designed to look clinical. It's a graph that is clinical.

Concentration curve view in Mynim
02

Twice daily. Every three days. Whatever works for you.

Standard GLP-1 apps give you one option: weekly. Mynim gives you full control over your dosing interval. Daily, twice daily, every few days, weekly.

Your protocol is your protocol. Mynim tracks it accurately regardless.

Injection site rotation map in Mynim
03

Stop guessing where you went last.

Visual body map. Front and back. Mynim tracks every injection site and when you last used it. A clear indicator shows where to go next.

Left abdomen, right thigh, upper arm. Rotate properly. Reduce tissue stress. It takes two taps.

Dose and symptom history in Mynim
04

Connect the dots between your dose and how you feel.

Log nausea, fatigue, and other side effects by severity after each dose. Track energy, mood, and mental clarity on a 1-10 scale.

Over time, patterns emerge. Mynim gives you the data to find out what is actually happening.

Three steps. Two minutes. Full visibility.
01

Pick your medication

Semaglutide, tirzepatide, or GLP-1/GIP combo. Mynim loads the right pharmacokinetic profile automatically.

02

Log your dose

Amount in mg, injection site, any notes. Takes ten seconds.

03

Watch the data build

Concentration curves update live. Symptoms trend over time. Patterns surface on their own.

Everything in one place.

Dose Logging

Track exact mg, timing, and notes in seconds with a dosing workflow built for split protocols.

Site Rotation

See exactly where you injected last and rotate confidently to reduce repeat-site irritation.

Symptom Tracking

Log nausea, fatigue, and mood with severity scores to expose real trends over time.

PDF Export

Generate complete dose history exports for your records or to review with your clinician.

MedicationsSemaglutide (Ozempic, Wegovy), Tirzepatide (Mounjaro, Zepbound), GLP-1/GIP combinations
Dose dataDate, time, amount (mg), injection site, notes
Body metricsWeight (with 30-day, 90-day, and all-time trends)
Side effectsNausea, fatigue, headache, and more. Tracked by severity: none, mild, moderate, severe.
Wellness scoresMental clarity, energy, mood. Scored 1 to 10.
ExtrasPDF export of your full dose history. Smart reminders on your schedule. Injection site rotation tracking.
$1.99/mo

That's it. One plan. Everything included. No tiers, no upsells, no "premium" features locked behind a higher price.

Start with a 7-day free trial. If Mynim isn't useful to you in a week, cancel. No questions. No friction.

Start Your Free Trial 7-day free trial, then $1.99/month. Cancel anytime in Settings. No tiers. No upsells.

FAQ

Your data stays on your device. Mynim does not upload your health information to any server.

The curve uses published pharmacokinetic parameters (half-life, Tmax, bioavailability) for each supported medication. It's a model, not a blood test. But it's built on real science, and it gives you a far better picture than guessing.

No. Mynim is a tracking tool. It models pharmacokinetic data based on published research, but it does not provide medical guidance. Talk to your doctor about your dosing protocol.

Semaglutide (sold as Ozempic and Wegovy), Tirzepatide (sold as Mounjaro and Zepbound), and GLP-1/GIP combination medications.

Yes. Mynim works for any dosing frequency. But it was designed specifically for people on non-standard schedules who need more than a basic reminder app.

Open Settings on your iPhone, tap Subscriptions, tap Mynim, tap Cancel. Done.

Mynim is currently available on iPhone only, exclusively through the Apple App Store. We're focused on building the best possible iOS experience right now. Android isn't on the roadmap yet, but if that changes, we'll say something.